No Data
No Data
Shandong Jincheng Pharmaceutical Group (300233.SZ): One of the actual controllers, Zhao Hongfu, plans to reduce his shareholding by no more than 3 million shares.
On July 12th, Gelunhui reported that Mr. Zhao Hongfu, one of the actual controllers, plans to reduce his shareholding in the company by no more than 3 million shares within 3 months after 15 trading days from the disclosure of this announcement through centralized bidding and bulk trading, accounting for no more than 0.7909% of the total share capital excluding the shares held in the company's repurchase account.
China Approves Changes to Shandong Jincheng's Antibiotic; Shares Up 3%
Shandong Jincheng Pharmaceutical Group (300233.SZ): the drug supplement application approval notice for injection of Cefoperazone sodium and Sulbactam sodium has been received.
On July 10th, Gelunhui reported that Shandong Jincheng Pharmaceutical Group (300233.SZ), the holding subsidiary, recently received a "Drug Supplementary Application Approval Notice" for injection cephalosporin and sulbactam sodium issued by the National Drug Administration. Injection cephalosporin and sulbactam sodium is a compound preparation composed of the third-generation cephalosporin and beta-lactamase inhibitor, which can be used alone to treat upper and lower respiratory tract infections caused by sensitive bacteria; upper and lower urinary tract infections; peritonitis, cholecystitis, cholangitis and other intra-abdominal infections; sepsis; meningitis; skin and soft tissue infections; bone and...
Shandong Jincheng Pharmaceutical Group (stock code: 300233.SZ): Injection Chloramphenicol Sodium Succinate obtained drug registration certificate.
Jincheng Pharmaceutical (300233.SZ) announced that its wholly-owned subsidiary Beijing Jincheng Teal Pharmaceuticals Co., Ltd. (referred to as "Jincheng Teal") has received an injection registration certificate for chlorpromazine issued by the National Medical Products Administration (Certificate Number: 2024S01517). The injection of chlorpromazine is registered as a Class 4 chemical drug and was approved based on the consistency evaluation of generic drug quality and efficacy. According to the website of the National Medical Products Administration, chlorpromazine is currently available in China in injection and tablet forms and is mainly used for short-term treatment of moderate to severe pain after surgery.
Shandong Jincheng Pharmaceutical Group (300233.SZ): Jincheng Taier's production lines of Oseltamivir phosphate active pharmaceutical ingredients and Progesterone active pharmaceutical ingredients have passed the pharmaceutical GMP compliance inspection.
On June 21, Gelunhui reported that Shandong Jincheng Pharmaceutical Group (300233.SZ) announced that its wholly-owned subsidiary, Beijing Jincheng Tail Pharmaceutical Co., Ltd. (referred to as "Jincheng Tail"), recently received the Drug GMP compliance inspection notice issued by the Beijing Municipal Drug Administration. The phosphoric acid oseltamivir and progesterone API production lines it applied for have passed the compliance inspection of the Drug Production Quality Management Standard. Phosphoric acid oseltamivir is the precursor drug of its active metabolic product (oseltamivir carboxyl salt), and oseltamivir carboxyl salt is a selective influenza virus neuraminidase inhibitor. Currently, oseltamivir phosphate is domestically...
Shandong Jincheng Pharmaceutical Group (300233.SZ): The revenue of hormone products in the first quarter increased by nearly 20% year-on-year, and the high growth trend continues to be maintained.
According to the Investors Relationship Activity Report disclosed by Shandong Jincheng Pharmaceutical Group (300233.SZ) on June 19th, the company's main hormone products include progesterone cream, progesterone soft capsules, chlorpheniramine maleate tablets (6/3), and other series of products. The revenue of hormone products in the first quarter of this year increased by nearly 20% year-on-year, continuing to maintain a high-growth trend. The company's "Langyi Gynecology" series brand continues to be developed, and the company will also consider introducing small and beautiful gynecological products through international cooperation to contribute new strength to the company's layout of "women's health technology".
No Data